


THIS WAY UP

Ulcerative Colitis?

dispose of a problem...

... How Predfoam helps solve the problems currently associated with local therapy:

- **DISPOSABLE APPLICATORS**
— Clean and simple to use
- **UNIQUE METERED DOSE AEROSOL**
— Ensures dosage uniformity
- **PREDNISOLONE METASULPHOBENZOATE**
— High local tissue levels* — 10-100 times those produced by enema formulations of prednisolone



PREDFOAM®

PREDNISOLONE METASULPHOBENZOATE

Prescribing Information

Presentation: A white mucoadherent aerosol foam containing prednisolone metasulphobenzate sodium equivalent to 20mg prednisolone per metered dose.

Uses: Treatment of proctitis and ulcerative colitis.

Dosage and Administration: One metered dose inserted rectally once or twice daily for two weeks, extending treatment for a further two weeks when a good response is obtained.

Contra-indications, warnings, etc:

Contra-indications: Local conditions where infection might be masked or healing impaired eg. peritonitis, fistulae, intestinal obstruction, perforation of the bowel.

Side effects: The consequences of systemic absorption should be considered with extensive use over prolonged periods. As with all rectal corticosteroids, prolonged continuous use is undesirable.

There is inadequate evidence of safety in human pregnancy.

Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate and intra-uterine growth retardation. There may therefore be a very small risk of such effects in the human foetus. Overdosage by this route is unlikely.

Legal Category : POM

PL 0108/0101

Pack and basic NHS price : Box containing 1 fourteen-dose canister, 14 disposable nozzles and 14 plastic bags £7.00

© Registered Trade Mark

References: (1) McIntyre, P.B. et al. (1985) GUT 26 822-824
(2) Rodrigues, C. et al. (1987) Lancet, June 27th, 1497.

Full information is available on request

PHARMAX LIMITED
Bourne Road, Bexley, Kent. DA5 1NX
Telephone 0322 91321

NEW

SPECIFICALLY DEVELOPED

THE IMPORTANCE OF NIGHT-TIME COVER

An important factor in the causation of duodenal ulcer is nocturnal intragastric acidity.^{1,2} During the day, production of gastric acid is desirable for natural digestion and as protection against unwanted ingested bacteria.

'Pepcid' PM, the first H₂-receptor antagonist indicated solely for once-nightly use.

'Pepcid' PM, when administered at night, effectively controls nocturnal acidity in most duodenal-ulcer patients, providing rapid healing and swift relief of pain.

'Pepcid' PM has been shown to achieve up to 91% (124 of 136 patients) healing of duodenal ulcers within six weeks⁴ and up to 81% (62 of 77 patients) of gastric ulcers within eight weeks.⁵

That's 'Pepcid' PM. A small, once-nightly 40 mg tablet supplied in a convenient 28-day calendar pack to help maximise compliance.

ABRIDGED PRODUCT INFORMATION ▼

Full prescribing information is available and should be consulted before prescribing.

INDICATIONS Duodenal ulcer; prevention of relapses of duodenal ulceration; benign gastric ulcer; hypersecretory conditions such as Zollinger-Ellison syndrome.

DOSAGE In duodenal and benign gastric ulcer, 40 mg at night for four to eight weeks.

For prevention of duodenal ulcer recurrence, 20 mg at night.

Initiate antisecretory therapy of Zollinger-Ellison syndrome with 20 mg every six hours and adjust to individual response. The maximum dosage used for up to one year was 480 mg daily.

CONTRA-INDICATION Hypersensitivity.

PRECAUTIONS Exclude any likelihood of gastric carcinoma before using 'Pepcid' PM.

Consider reducing the daily dose if creatinine clearance falls to or below 30 ml/min.

'Pepcid' PM is not recommended in pregnancy, nursing mothers or children.

SIDE EFFECTS Rarely, headache, dizziness, constipation, diarrhoea. Less frequently, dry mouth, nausea, vomiting, rash, abdominal discomfort, anorexia, fatigue.

BASIC NHS COST 20 mg tablets, £14.00 for 28-day calendar pack and £25.00 for bottles of 50.

40 mg tablets, £26.60 for 28-day calendar pack and £47.50 for bottles of 50.

Product Licence Numbers: 20 mg tablets, 0025/0215; 40 mg tablets, 0025/0216.

▼ Special reporting to the CSM required.

Issued January 1988.


TM denotes trademark

References

1. Gledhill, T., *et al.*, *Gut*, 1983, 24, 904.
2. Ireland, A., *et al.*, *Lancet*, 1984, ii, 274.
3. Santana, I. A., *et al.*, *Postgrad. med. J.*, 1986, 62 (Suppl. 2), 39.
4. Mann, S. G., Cottrell, J., *Ital. J. Gastroenterol.*, 1987, 19 (Suppl. 3), 68.
5. Data on file, Merck Sharp & Dohme Research Laboratories.




Thomas Morson Pharmaceuticals
Hertford Road, Hoddesdon, Hertfordshire
Division of Merck Sharp & Dohme Limited



FOR ONCE-NIGHTLY USE

NIGHT-TIME COVER FROM A SINGLE DOSE³



Adapted from Reference 3.

Mean hourly intragastric H⁺ activity in healthy subjects taking one dose of either famotidine 40 mg, ranitidine 300 mg or placebo.³

PEPCIDTM PM

40 mg

(famotidine)

One at night can make their day

NEW

For the relief of symptoms of

DUMPING SYNDROME

*“The favourable effect of the addition of guar gum to the meals of patients suffering from the dumping syndrome is based on the normalization (i.e. slowing down) of the passage of food from the stomach to the duodenum and jejunum, and hence the slowing down of the absorption of nutrients, especially monosaccharides, and the prevention of a rapid postprandial increase in intraluminal osmolarity in the duodenum.”*⁶

- ★ slows gastric emptying¹⁻³
- ★ binds bile acid⁸
- ★ reduces hyperglycaemia and hyperinsulinaemia⁴⁻⁵
- ★ helps improve patient comfort, food tolerance and nutritional status⁶⁻⁷

Guarem[®]

Guar 5g

References: 1 Jenkins et al *Br.Med.J.* 1978, 1, 1392 2 Blackburn et al *Clin.Sc.* 1984, 66, 329 3 Leeds et al *Lancet* 1981, 1, 1075 4 Jenkins *Proc.Soc.Exp.Biol.* 1985, 180, 422 5 Fuesell et al *Pract.Diab.* 1986, 3, 258 6 Harju & Larmi *J.Parent.Ent.Nutr.* 1983, 7, 470 7 Harju & Makela *Amer.J.Gastroent.* 1984, 79, 861 8 Hanson et al *Hepato-Gastroent.* 1983, 30, 161

Clinical Information

Action. Guar gum which is derived from natural sources is a high molecular weight polysaccharide, galactomannan. In solution it (i) increases gastric transit time and (ii) slows the rate of absorption of other carbohydrates leading to a reduction in post-prandial hyperglycaemia and insulin secretion. Guar gum is not absorbed and remains chemically unchanged until it reaches the colon where it is broken down before excretion. **Indication.** The relief of the symptoms of the 'dumping syndrome'. **Dosage & Administration.** Adults One 5g sachet to be taken with each main meal. The contents of a sachet are preferably sprinkled evenly over a meal on the plate or stirred into suitable foods (e.g. tomato juice, yoghurt, muesli, etc), in which case the food should be accompanied by a drink of 150ml (½ tumbler). **Contra-Indications, Warnings, etc.** To avoid any risk of oesophageal obstruction or rupture, this

product should not be given to patients with a history of oesophageal disease or difficulty in swallowing. While Guarem may be expected to reduce malabsorption, usual monitoring of nutritional status should be continued. Guarem should not be ingested as dry granules. **Side-Effects.** Gastro-intestinal symptoms (flatulence, diarrhoea) are quite common at the commencement of treatment. These can be reduced or avoided by initiating treatment gradually, in accordance with advice on the pack. **Presentation.** Sachets, each containing guar gum granules 5 grams. The fine pale cream granules are tasteless and readily water-miscible. Cartons of 100 sachets. **Product Licence Numbers:** PL0237/0023 & 0026. PA 3/61. Further information available from Rybar Laboratories Ltd., Amersham, Bucks, UK.

Rybar



Rapid relief for patients gripped by IBS

Colofac rapidly relieves the symptoms of Irritable Bowel Syndrome by a direct action on colonic smooth muscle.

Colofac eliminates spasm without the anti-cholinergic side effects that can prove troublesome to the patient.

colofac[®] 
mebeverine
loosens the grip of IBS


Prescribing Information

Presentation: White, sugar-coated tablets each containing 135mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. Yellow, banana-flavoured sugar-free suspension containing mebeverine pamoate equivalent to 50mg mebeverine hydrochloride per 5ml. Available in bottles of 300ml. Basic NHS price £3.50.
Indications: 1. Irritable bowel syndrome. 2. Gastro-

intestinal spasm secondary to organic diseases.
Dosage and Administration: Tablets: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. Suspension: Adults and children ten years and over: 15ml (150mg) three times a day, preferably 20 minutes before meals. **Contra-indications, warnings, etc:** Animal experiments have failed to show any terato-

genic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **Product Licence Number:** Tablets: 0512/0044; Suspension: 0512/0061. Further information is available on request to the Company. Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD. Telephone: 0703 472281

duphar



Colifoam gives your patients much greater personal freedom in their daily lives.^{1,2}

So, while steroid enemas may equal Colifoam's effectiveness clinically,^{1,2} when it comes to patient preference there's no comparison.

Colifoam is also unique among foam treatments with an unrivalled 12 years of proven efficacy and safety in clinical practice. It's a success record that makes Colifoam, more than any other, a prescription of confidence.



The proven choice in distal inflammatory bowel disease

1. Ruddlel WSJ et al. *Gut* 1980; 21: 885-889

2. Somerville KW et al. *British Medical Journal* 1985; 291: 866

PRESCRIBING INFORMATION: Presentation: White odourless aerosol containing hydrocortisone acetate PhEur 10%. Uses: Ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration: One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). Contra-indications, warnings etc.: Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions: Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Keep out of reach of children. For external use only. Legal category: POM. Package Quantity & Basic NHS cost: 25g canister plus applicator, £7.25. Further Information: One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No.: 0036/0021. Further information is available on request.


Stafford-Miller Ltd., Professional Relations Division, Hatfield, Herts. AL10 0NZ.

ASACOL

(MESALAZINE)*

Direct delivery to the colon

For ulcerative colitis patients
who cannot tolerate
sulphasalazine¹



ASACOL delivers 5-amino-salicylic acid directly to the colon without sulphapyridine (the agent in sulphasalazine that can cause distressing side effects).²

A patented acrylic coating on **ASACOL** makes it site selective. **ASACOL** remains intact until it reaches the terminal ileum or colon, where pH rises above 7 and dissolves the coating, releasing the 5-ASA.^{2,3}

Each **ASACOL** tablet provides twice as much 5-ASA (400 mg) as each tablet of sulphasalazine (200 mg), which allows patients to take fewer tablets daily.

Clinical studies have shown that **ASACOL** offers efficacy comparable to that of sulphasalazine in maintaining the remission of ulcerative colitis.⁴

ASACOL

Direct Delivery to the Colon

ABBREVIATED PRESCRIBING INFORMATION PRESENTATION

Red tablets containing 400 mg of mesalazine (5-aminosalicylic acid) coated for release in the terminal ileum and colon.

USES

For the maintenance of remission of ulcerative colitis in patients who cannot tolerate sulphasalazine.

DOSAGE AND ADMINISTRATION

Adults: 3 to 6 tablets daily in divided doses. There is no dose recommendation for children.

CONTRA-INDICATIONS, WARNINGS, ETC.

Contra-indications

Contra-indications: a history of sensitivity to salicylates. Children under 2 years of age.

Precautions

Renal disorder. Mesalazine is excreted rapidly by the kidney mainly as its metabolite, N-acetyl 5-aminosalicylic acid. In rats large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Although no renal toxicity has been reported in patients taking 'Asacol', it is not recommended in patients with renal impairment and caution should be exercised in patients with a raised blood urea or proteinuria.

Asacol should not be given with lactulose or similar preparations which lower stool pH and may prevent release of mesalazine.

Use during pregnancy

Use of 'Asacol' during pregnancy should be with caution, and only if, in the opinion of the physician, the potential benefits of treatment are generally greater than the possible hazards.

Adverse Reactions

Adverse reactions occur in a small proportion of patients who previously could not tolerate sulphasalazine. The side-effects are predominantly gastrointestinal (nausea, diarrhoea and abdominal pain) and headache. 'Asacol' may be associated with the exacerbation of the symptoms of colitis in those patients who have previously had such problems with sulphasalazine.

Other side effects observed with sulphasalazine such as depression of bone marrow and of sperm count and function, have not been reported with 'Asacol'.

LEGAL CATEGORY: POM. PL: 0424/0032.

Daily treatment cost: 66p-£1.31

Licence Holder:

Tillotts Laboratories, Henlow Trading Estate, Henlow, Bedfordshire SG16 6DS.

Supplier:

Smith Kline & French Laboratories Limited, Welwyn Garden City, Hertfordshire AL7 1EY

U.K. Patent No. 8322387

REFERENCES:

1. Dew M.J., Harries A.D., Evans B.K. et al. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. *Lancet*, 1983; ii:801.
2. Dew M.J., Hughes P.J., Lee M.G. et al. An oral preparation to release drugs in the human colon. *Br. J. Clin. Pharmacol.*, 1982; 14:405-408.
3. Dew M.J., Ryder R.E.J., Evans N. et al. Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. *Br. J. Clin. Pharmacol.*, 1983; 16:185-187.
4. Dew M.J., Hughes P.J., Harries A.D. et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. *Br. Med. J.*, 1982; 285:1012.
5. Dew M.J., Harries A.D., Evans N. et al. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. *Br. Med. J.*, 1983; 287:23-24.

*Mesalazine is the British Approved name for 5-aminosalicylic acid.

SK&F Smith Kline & French Laboratories Limited
A SMITH-KLINE BECKMAN COMPANY
Welwyn Garden City, Hertfordshire AL7 1EY

© 1987 Smith Kline & French Laboratories Limited. 'Asacol' is a trade mark. ASC AD37

Protect your patients ag



REFERENCES: 1. Lee, F. et al, *The Lancet*, (8 June 1985); 1299-1302. 2. Ward, M. et al, *Digestion* (1986); 34: 173-177. 3. Martin, D. et al, *The Lancet*, (3 January 1981); 7-10. 4. Hamilton, I. et al, *Gut*, (1986); 27: 106-110. 5. Bianchi Porro, G. et al, *The Lancet*, (22 September 1984); 698. 6. Konturek, S. et al, *Gut*, (1987); 28: 201-205. 7. Marshall, B. et al, *The Lancet*, (16 June 1984); 1311-1315. 8. Coghlan, J. et al, *The Lancet*, (14 November 1987); 1109-1111.

PRESENTATION: Each tablet or 5 ml dose contains 120 mg tri-potassium di-citrate bismuthate (calculated as Bi_2O_3). **USES:** Ulcer healing agent. For the treatment of gastric and duodenal ulcers. **DOSAGE AND ADMINISTRATION:** By oral administration. **Adults:** The more convenient dosage is two tablets or two 5 ml spoonfuls twice daily (half an hour before breakfast and half an hour before the evening meal) for 28 days. If necessary a further month's treatment may be given. Maintenance therapy with De-Nol is not indicated, but treatment may be repeated after an interval of one month. The tablets are to be taken with a draught of water and each 10 ml dose of the liquid diluted with 15 ml of water. **Children:** Not recommended.

Gist-brocades

ainst ulcer relapse.

NEW DOSAGE 2 b.d.,
NEW FORMULATION.

Initial treatment with De-Nol, rather than an H₂ antagonist, heals ulcers just as effectively,^{1,2} but significantly reduces the risk of relapse.^{3,4} And without the need for maintenance therapy.⁵

The mechanism underlying this important clinical benefit would appear to be a combination of De-Nol's cytoprotective properties⁶ with an antibacterial activity against *Campylobacter pylori*,⁷ the bacterium now shown to be an important predictive factor in the relapse of duodenal ulcer disease.⁸

So if you want to protect your patients against relapse, prescribe new formulation De-Noltab, 2 b.d.

 De-Noltab 2 b.d.

De-Nol[®]


tri-potassium di-citrate bismuthate

CONTRA-INDICATIONS, WARNINGS: De-Nol/De-Noltab should not be administered to patients with renal disorders and, on theoretical grounds, is contra-indicated in pregnancy. **Special precautions:** De-Nol/De-Noltab may inhibit the efficacy of orally administered tetracyclines. **Side effects:** Blackening of the stool usually occurs; nausea and vomiting have been reported. Darkening of the tongue may occur with De-Nol liquid only. **Overdosage:** No reports of overdosage have been received; gastric lavage and, if necessary, supportive therapy would be indicated. **LEGAL CATEGORY:** P. **PACKAGE QUANTITIES:** De-Noltab: Treatment pack of 112 tablets. De-Nol: Treatment pack of 560 ml. **BASIC N.H.S. PRICE:** De-Noltab: £20.98. De-Nol: £14.65. **PRODUCT LICENCE NUMBERS:** De-Noltab: 0166/0124. De-Nol: 0166/5024.

Brocades/Great Britain/Limited, West Byfleet, Surrey.

REBALANCES THE
ULCER EQUATION


The Evoxin Effect




↓ mediated outside the blood-brain barrier via the chemoreceptor trigger zone and the G.I. tract.



↓ resolves gastric stasis, accelerates emptying.



↓ relieves dyspeptic nausea more effectively than metoclopramide.^{1,2}



EvoxinTM
domperidone


a move in the right direction
for relief of dyspeptic nausea

▼ Achieves symptomatic relief of gastric nausea and vomiting from any cause (NDA for chronic use). Also for treatment of Dyspepsia for up to 12 weeks. Evoxin is a potent prokinetic agent which is significantly more effective than metoclopramide. Evoxin is available in oral tablets (10mg and 20mg) and in blister strips of 10. Basic NHS cost £1.90. Evoxin is a registered trademark of Janssen Pharmaceutica.

© Janssen Pharmaceutica, 1996. Evoxin is a registered trademark of Janssen Pharmaceutica. All rights reserved. Janssen Pharmaceutica, Turnhout, Belgium. Evoxin is a registered trademark of Janssen Pharmaceutica. All rights reserved. Janssen Pharmaceutica, Turnhout, Belgium. Evoxin is a registered trademark of Janssen Pharmaceutica. All rights reserved. Janssen Pharmaceutica, Turnhout, Belgium.

Coated VICRYL*

(polyglactin 910)



Surgeons are turning to
Coated VICRYL.



TECHNICAL DATA

COATED VICRYL* (POLYGLACTIN 910) STERILISED BRAIDED SYNTHETIC ABSORBABLE SUTURE

Presentation The basic VICRYL (Polyglactin 910) Suture is prepared from a copolymer of glycolide and lactide. The substances are derived respectively from glycolic and lactic acids. The empirical formula of the copolymer is $(C_2H_2O_2)_m(C_3H_4O_2)_n$.

Coated VICRYL (Polyglactin 910) Sutures are obtained by coating the braided suture material with a mixture composed of a copolymer of glycolide and lactide and an equal amount of calcium stearate. This coating does not affect the biological properties of the suture.

Coated VICRYL (Polyglactin 910) Sutures are coloured by adding D & C Violet No 2 during polymerisation of the lactide and glycolide. Sutures may also be manufactured in the undyed form.

These sutures are relatively inert, nonantigenic, nonpyrogenic and elicit only a mild tissue reaction during absorption.

Action: Two important characteristics describe the in vivo behaviour of absorbable sutures. The first of these is tensile strength retention and the second, absorption rate or loss of mass.

Subcutaneous tissue implantation studies of Coated VICRYL Suture in rats show at two weeks post-implantation approximately 55% of its original tensile strength remains, while at three weeks approximately 20% of its original strength is retained.

Intramuscular implantation studies in rats show that the absorption of these sutures is minimal until about the 40th post-implantation day. Absorption is essentially complete between the 60th and 90th days.

Uses Coated VICRYL synthetic absorbable sutures are intended for use where an absorbable suture or ligature is indicated.

Dosage and Administration

By implantation.

Contra-indications, Warnings, etc.

These sutures, being absorbable, should not be used where extended approximation of tissues under stress is required.

Sutures placed in skin and conjunctiva may cause localised irritation if left in place for longer than 7 days and should be removed as indicated.

At the discretion of the surgeon, appropriate non-absorbable sutures may be used to provide additional wound support when Coated VICRYL sutures are used in ophthalmic procedures.

The safety and effectiveness of Coated VICRYL (Polyglactin 910) Sutures in neural tissue and in cardiovascular tissue have not been established.

Pharmaceutical Precautions

Do not re-sterilise.

Legal Category.

Not applicable.

Package Quantities Various lengths of material packaged in sealed aluminium foil sachets. This primary pack is contained in a peel-apart secondary pack. The unit of sale is 12 packs contained in a film wrapped drawer style carton.

Further Information No suture related adverse reactions were reported during clinical trials, although a number of minor reactions were classified as being of unknown cause.


Product Licence No 0508/0009
Br. Pat. No. 1583390

Date of Preparation of Data Sheet April 1981
Revised ... 1987

**ETHICON LTD.
PO BOX 408, BANKHEAD AVE
EDINBURGH EH11 4HE**

Coated VICRYL*


(polyglactin 910)



More Surgeons are turning to
Coated VICRYL.



STRENGTH AGAINST REFLUX*



In the management of reflux oesophagitis and hiatus hernia the role of Liquid Gaviscon is well established. Liquid Gaviscon deals with reflux simply and physically by forming a neutral layer or 'raft' on gastric contents to inhibit reflux and so bring effective relief of reflux-related upper gastro-intestinal symptoms.

More recently an in-vitro comparison¹ using computer-based techniques, has shown that Liquid Gaviscon produces a 'raft' more resistant to upward pressures than any other alginate-containing compound tested.

Liquid GAVISCON[®]

Sodium Alginate BPC, Sodium Bicarbonate Ph.Eur.,
Calcium Carbonate Ph.Eur.

a logical choice in reflux

Prescribing Information

Active Ingredients: Sodium Alginate BPC 500mg, Sodium Bicarbonate Ph.Eur. 267mg per 10ml; Calcium Carbonate 160mg per 10ml dose. **Indications:** Heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia and reflux oesophagitis. **Contra-indications:** None known.

Dosage and Administration: Adults, children over 12: 10-20ml liquid after meals and at bedtime. Infants: not recommended. Children under 12: 5-10ml liquid after meals and at bedtime.

Note: 10ml liquid contains 6.2mmol sodium. **Basic NHS Cost:** As at Jan. 1988: 500ml liquid £2.88, Irish Price IR £3.72.

PL: 44/0058. **Irish P.A. No.:** 27/12/1.

Reference


1. Washington, N. *et al.*, *Int. J. Pharmaceut.* (1986) **28**, 139-143
Further information is available on request.
Reckitt & Colman Pharmaceutical Division,
Hull HU8 7DS.

*Registered trade mark.



Coated VICRYL^{*}

(polyglactin 910)



More and more Surgeons are
turning to Coated VICRYL.

Coated VICRYL^{*}
(polyglactin 910) braided sutures

ETHICON
a Johnson & Johnson company

ETHICON Ltd., P.O. Box 408, Bankhead Avenue,
Edinburgh EH11 4HE, United Kingdom.
^{*}Trademark © ETHICON Ltd 1988.

Re-educate the constipated bowel

**FYBOGEL
ORANGE**


Ispaghula husk B.P.



gently does it



Active ingredients: Each sachet contains 3.5g Ispaghula husk BP. **Indications:** Conditions requiring a high-fibre regimen. **Dosage and Administration:** (To be taken with water) Adults and children over 12: One sachet morning and evening. Children under 12: One half to one level 5ml spoonful depending on age and size, morning and evening. **Contra-indications, Warnings, etc.:** Fybogel is contra-indicated in cases of intestinal obstruction and colonic atony. **Basic NHS Price:** At Feb. '88 60 sachets £4.24, Eire: 60 sachets IR £4.92. **PL No.:** Fybogel Orange 44/0068, Fybogel 44/0041. **Irish P.A. No.:** Fybogel Orange 27/2/2, Fybogel 27/2/1. Fybogel is a registered trademark. Further information is available from: Reckitt & Colman Pharmaceutical Division, Hull HU8 7DS.



The BMJ's new series of books of general interest by medical writers

Not Always on the Level by E J Moran Campbell. Romantic memories of a Yorkshire childhood; hilarious ones of student days in London; a detailed and fascinating account of Campbell's pioneering work in respiratory physiology; and a painfully honest description of what it is like to a manic depressive.

Price: Inland £14.95; Abroad £18.50; U.S.A\$30.00
B.M.A. members: Inland £13.95; Abroad £17.50; U.S.A\$28.00

Recollections and Reflections by Douglas Black, who recalls episodes from his remarkable career—in which he has been professor of medicine at Manchester University, chief scientist at the DHSS, and president of the Royal College of Physicians—and reflects on the practice and progress of medicine, university teaching and administration, public service, and life in general.

Price: Inland £14.95; Abroad £17.50; U.S.A\$29.00
B.M.A. members: Inland £13.95; Abroad £16.50; U.S.A\$27.00

Doctors in Science and Society by Christopher Booth, who examines the lives and times of some eighteenth century medical scientists and the role of their present day successors. A must for anyone interested in the past and future of medical science.

Price: Inland £14.95; Abroad £19.50; U.S.A\$32.00
B.M.A. members: Inland £13.95; Abroad £18.50; U.S.A\$30.00

All prices include postage, by air abroad
Please enclose payment with order

ORDER FROM: British Medical Journal
PO Box 295, London WC1H 9TE
or any leading medical bookseller

Pyrogastrone Tablets

carbenoxolone, aluminium hydroxide and magnesium trisilicate in an alginate base

For the treatment of oesophageal inflammation, erosions and ulcers due to hiatus hernia or other conditions causing gastro-oesophageal reflux, and for the relief of heartburn, flatulence and other symptoms associated with reflux oesophagitis. Each tablet contains Carbenoxolone Sodium BP 20mg, Dried Aluminium Hydroxide PhEur 240mg and Magnesium Trisilicate BP 60mg in a base containing Sodium Bicarbonate BP 210mg and Alginic Acid BPC 600mg. Each tablet contains 59.2mg (2.6mmol) Na.

Adult dosage: One tablet to be chewed immediately after meals, three times a day, and two to be chewed at bedtime.

Elderly: Not recommended for patients over 75 years of age; otherwise as for adults, but see "precautions".

Children: Not recommended.

Cartons of 100 foil-packed tablets. Basic NHS cost of one day's treatment £1.16 (5 tablets). PL 0071/0138.

Contra-indications: Hypokalaemia, cardiac, renal or hepatic failure.

Precautions: Pyrogastrone should not be given to patients on digitalis therapy unless serum electrolyte levels are monitored weekly and measures taken to prevent the development of hypokalaemia. Special care should be exercised with patients predisposed to sodium and water retention, potassium loss and hypertension (e.g. the elderly and those with cardiac, renal or hepatic disease) since the carbenoxolone content of Pyrogastrone can induce similar changes. Regular monitoring of weight, blood pressure and clinical state, which should indicate the development of such effects is advisable for all patients.

If hypokalaemia occurs Pyrogastrone should be withdrawn and potassium loss should be corrected by the administration of supplements. Although animal studies have shown no hazard, there is inadequate evidence of the safety of carbenoxolone in human pregnancy. Pyrogastrone should therefore be avoided in those who are pregnant. Pyrogastrone is a registered trade mark. Made under licence from Biorex Laboratories Ltd., England. Brit. Pat. No. 1390683. Further information available from Winthrop Laboratories, Onslow Street, Guildford, Surrey GU1 4YS.

I. Curr. Med. Res. Opin. 1978; 5/8: 637-644

WINTHROP

(W2047)388

Routes to relief of reflux oesophagitis



Alginate protection

Designed to protect the oesophagus by impeding gastro-oesophageal reflux, the alginate component of Pyrogastrone is derived from the knotted wrack seaweed (*Ascophyllum nodosum*).

Buffering antacids are added for symptom relief.

Active healing

Added to an alginate antacid, low-dose carbenoxolone can enhance the rate of symptom relief and significantly increase healing of oesophagitis. This active healing component of Pyrogastrone is synthesised from glycyrrhizic acid, a constituent of liquorice root.

Pyrogastrone

carbenoxolone, aluminium hydroxide
and magnesium trisilicate in an alginate base

merging the routes to relief

24-h-pH-Metry will become Routine in Gastroenterology


using the new **Gastrograph pH** with the new **Agar pH Electrode** (no skin reference)

For the Practitioner:

No Computer or other ancillary equipment is necessary. The **Gastrograph** is its own Computer, pH-Meter and Printer - all combined in one. The printout is available in minutes.

For the Investigator:

The printout can be complemented by transferring the data to another PC. Either you can use your own statistics on the raw data - or we also supply statistics packages for a single patient, groups of 20 patients or groups of 200 patients, including graphics.



MIC AG, Medical Instruments Corporation, CH 4502 Solothurn, POB 706, Friedhofplatz 16,
Tel. 41-65-234355-56, Telex 931486 mic ch, FAX 41-65-221792

Lets ulcers heal by night and the stomach work by day

A single evening dose of Axid suppresses acid production only during the night¹ when mucosal damage may occur.

Because of its short half-life, Axid then produces minimal suppression of daytime gastric acid.

Axid produces effective ulcer healing²⁻⁴ whilst allowing the stomach to work virtually normally during the day.

NEW
AXID 300mg

NIZATIDINE
ONCE NIGHTLY H₂ ANTAGONIST

▼ **ABBREVIATED PRESCRIBING INFORMATION.** Presentation: Capsules containing 150mg or 300mg nizatidine INN. Uses: For the treatment of duodenal and benign gastric ulcer, and prevention of duodenal ulcer recurrence. Dosage and Administration: (For full information, see data sheet). Axid is administered orally. Adults: For duodenal and benign gastric ulcer, the recommended daily dose is 300mg in the evening for 4 or, if necessary, 8 weeks. For prevention of duodenal ulcer recurrence, the recommended daily dose is 150mg in the evening. The elderly: Normally dosage modification is not required except in patients who have moderate to severe renal impairment. Children: Not recommended. Patients with impaired renal function: Moderate renal impairment (creatinine clearance less than 50ml/min), the dose should be reduced by 50% to 150mg in the evening. Severe renal impairment (creatinine clearance less than 20ml/min), the dose should be reduced by 75%, to 150mg on alternate days. Prevention of duodenal ulcer recurrence in moderate renal impairment (creatinine clearance less than 50ml/min), the dose may be reduced to 150mg on alternate days. Severe renal impairment (creatinine clearance less than 20ml/min), the dose may be reduced to 150mg every third day. Contra-indication: Known hypersensitivity to H₂-receptor antagonists. Warnings: Usage in pregnancy: The safety of nizatidine for use during pregnancy has not been established. Usage in lactation: Administer to nursing mothers only if considered absolutely necessary. Drug interactions:

No interaction has been observed between nizatidine and aminophylline, theophylline, chlordiazepoxide, diazepam, metoprolol, warfarin or lorazepam. Nizatidine does not inhibit the hepatic cytochrome P450-linked drug metabolising enzyme system. Precautions: Patients with impaired liver or kidney function should be treated with caution (see data sheet). Side-effects: Possible side-effects include headache, asthenia, chest pain, myalgia, abnormal dreams, somnolence, rhinitis, pharyngitis, cough, pruritus, sweating and reversible, asymptomatic elevations of transaminases. Overdosage: There is no experience of overdose in humans. Tested at very high doses in animals, nizatidine has been shown to be relatively non-toxic. Treatment: Symptomatic and supportive therapy is recommended. Activated charcoal may reduce nizatidine absorption and haemodialysis may remove absorbed nizatidine. Legal Category: POM Product Licence Numbers: Capsules 150mg 0006/0230. Capsules 300mg 0006/0231. Basic NHS Cost: Per 28 day calendar pack - 150mg capsules £13.44, 300mg capsules £25.76. Date of Preparation: August

1987. Full prescribing information is available from: Eli Lilly & Company Limited, Dextra Court, Chapel Hill, Basingsstoke, Hampshire RG21 2SY. Telephone: (0256) 473241. References: 1. Dammann HG *et al*, Scand J Gastroenterol 1987; 22: 56. 2. Simon B *et al*, *Ibid* 61. 3. Naccarato R *et al*, *Ibid* 71. 4. Cerulli MA *et al*, *Ibid* 79. 'AXID' is a Lilly trademark.



GASTROENTÉROLOGIE CLINIQUE ET BIOLOGIQUE

Gastroenterol Clin Biol, t. 12.

N° 1

January 1988

CONTENTS

DIGESTIVE TRACT AND PANCREAS

Editorial:

- Reflux esophagitis in 1987..... 2
A. BLUM and S. BONFILS

Editorial:

- Distal constipation, straining at stools, and fecal incontinence..... 3
Ph. DENIS

Original articles:

- Terminal constipation with abdominopelvic asynchronism: analysis of etiological, clinical and manometric findings, and of the results of biofeedback therapy
Y. EMERY, L. DESCOS, P. MEUNIER, D. LOUIS, G. VALANCOGNE and G. WEIL..... 6

- Persistence of circadian rhythms in gastric acid, gastrin, and pancreatic polypeptide secretions despite loss of cortisol and body temperature rhythms in man under stress (in English)..... 12
D. RIGAUD, J. P. ACCARY, J. CHASTRE, M. MIGNON, J. P. LAIGNEAU, A. REINBERG and S. BONFILS

- Famotidine has no significant effect on gonadal function in man (in English)..... 19
V. SAVARINO, M. GIUSTI, P. SCALABRINI, D. BESSARIONE, M. R. MAGNOLIA, G. PERCARIO and G. CELLE

- The usefulness of computed tomography in esophageal carcinoma. A prospective and « blind » study..... 23
B. GAYET, J. FRIJA, J. CAHUZAC and F. FÉKÉTÉ

Current trend:

- Epidemiologically linked cancers: risk factors for colorectal cancer?..... 29
O. INK, L. BEAUGERIE, J. C. RIERA and J. P. ÉTIENNE

LIVER AND BILIARY TRACT

Editorial:

- Cholelithiasis in cirrhosis: yes, but why?..... 37
T. DAVION and J. P. CAPRON

Original articles:

- Cirrhosis and cholelithiasis in France. A postmortem study..... 39
D. SAMUEL, E. SATTOUF, C. DEGOTT and J. P. BENHAMOU

- Extrahepatic digestive surgery in cirrhotic patients: mortality, morbidity, preoperative prognostic factors... 43
J. P. ZARSKI, P. BICHARD, P. BOURBON, A. TOURNERY, J. DEMONGEOT and M. RACHAIL

Current trend:

- Drug hepatotoxicity: actualization of a data bank of hepatic injuries and related drugs..... 48
M. BLOUR, R. POUPON, Y. CALMUS, J.-D. GRANGÉ, J.-D. HAMEL, V.-G. LÉVY, F. BODIN and G. CHEYMO

Clinical cases:

- Arteriovenous malformation of the caecum: report of two cases treated by embolization..... 61
D. PARIENTE, P. CAUQUIL, C. GALLAIRE and A. ROCHE

- Esophageal papillomatosis in an adult woman..... 66
F. FÉKÉTÉ, O. CHAZOUILLÈRES, V. GANTHIER, G. MOLAS and F. POTET

- Liver damage after administration of metopramine... 71
J. C. BARBARE, J. P. LATRIVE, E. KALOUSTIAN, G. BROQUIE, C. LEGENDRE and R. POUPON

Letters to the editors:

- Usefulness of manometry in colonic inertia..... 74
B. BASSOTTI

- Constipation: the role played by depression is underestimated by gastroenterologists..... 74
B. MAROY and Ph. MOULLOT

- Answer: J. Frexinos..... 75

- Action of cisapride on the orocecal transit time of a dyspeptogenic meal in the healthy subject..... 75
M. A. BIGARD, B. DURIVAUX and B. FRAITAG

- IgA linear bullosa dermatitis associated with Crohn's disease..... 76
C. BARBERIS, M. S. DOUTRE, P. BIOLAC-SAGE, E. POMPOUGNAC, C. BEYLOT and A. QUINTON

- Cholelithiasis in cirrhosis: prevalence and risk factors in 150 patients..... 77
B. DESAINT, J. F. CADRANEL, A. PAUWELS, J. TURK, M. CONRAD, C. FLORENT and V.-G. LÉVY

- Drug hepatotoxicity: data bank accessible by minitel
J. P. VINEL, C. MESKENS, P. CALÈS, J. P. CAUCANAS and J. P. PASCAL..... 78

- Piroxicam-induced hepatitis..... 79
K. HONEIN, P. ATTALI, G. PELLETIER and O. INK

- Maprotiline-induced benign acute hepatitis..... 80
A. PRUDENT, B. MARCHETTI, D. PIGNOL, G. LACROIX, G. BOUCKSON and M. LEGRÉ

- Obstructive jaundice: a rare complication of solitary non-parasitic liver cyst..... 80
J. KALOUCHE, F. DUPARC, B. BOKOBZA, Y. SURLEMONT, F. MICHOT and P. TENIERE

Subscriptions

Annual subscription — 10 issues/year

1988 : 144 US \$

Please contact : S.P.P.I.F., Z.I., B.P.22 — 41350 Vineuil (France)

SELECTIVE ANTISPASMODIC

FREES THE IBS PATIENT FROM THE GRIP OF SPASM



Further information is available from:

Norgine

Norgine Limited, 116-120 London Road,
Oxford OX3 9BA.

Norgine is a British company

Spasmonal and Norgine are trademarks

Spasmonal
Trade Mark

alverine citrate

493UK/78A/O1M

ABC OF AIDS

EDITED BY MICHAEL W ADLER

Today's most widely known and perhaps most generally feared disease, AIDS presents particular problems for non-specialist doctors. So far treatment of patients with AIDS has been largely confined to specialist centres so that, although the disease will inevitably spread, few doctors have had much experience of managing it. The *ABC of AIDS* provides essential details on the development of the epidemic, management of early HIV infection, tumours, and the respiratory, neurological, and gastrointestinal manifestations. It discusses the treatment of infections and the prospects for vaccines and prevention as well as outlining programmes for counselling, nursing, and the control of infection. Edited by Michael Adler, a leading authority on the topic, the *ABC of AIDS* is a vital guide that no medical practitioner can afford to be without.

**The facts
and
the future**

Price: Inland £9.95
Abroad £12.50/USA\$21.00
BMA members:
Inland £8.95
Abroad £11.50/USA\$19.00
including postage, by air
abroad

**Payment must be enclosed
with order**

Order from
British Medical Journal
P.O. Box 295
London WC1H 9TE
or any leading bookseller

The latest Keynes Press publication marks the ninetieth anniversary of a major breakthrough in tropical medicine

This day designing God
 Hath put into my hand
 A wondrous thing. And God
 Be praised. At His command,

I have found thy secret deeds
 Oh million-murdering Death.

I know that this little thing
 A million men will save—
 Oh death where is thy sting?
 Thy victory oh grave?

Not many scientists are moved to verse by the fruits of their research, but few results are as momentous as the one celebrated by Ronald Ross in *The Great Malaria Problem and its Solution*. Adapted from Ross's memoirs, this Keynes Press edition gives the full story of Ross's discovery of the mode of transmission of malaria by the Anopheles mosquito. Engagingly written, it is the frank and accurate picture of four years' painstaking work, full of hope, despair, elation, frustration, and what Ross describes as the "sacred passion for discovery." It also shows the close and moving scientific partnership between Ross and Patrick Manson, the "father of tropical medicine", as evidenced in the 155 letters exchanged between them over this period.

Fully illustrated, and with an introduction by L J Bruce-Chwatt, emeritus professor of tropical public health at the University of London, this unique volume provides a fascinating insight into the process of scientific research as well as a self portrait of one of the most impressive and colourful individuals in the history of tropical medicine.

Order from:
British Medical Journal (Keynes Press)
PO Box 295, London WC1H 9TE



(From a Mauritian Newspaper, 1908.)

THE KEYNES PRESS



The Keynes Press
 Limited editions of medical classics,
 handsomely printed and bound.

Price: Inland £45.00; Abroad £52.00;
 USA \$73.00, including postage.

Review: Role of Epidermal Growth Factor in Gastroprotection and Ulcer Healing	<i>S. J. Konturek</i>	129
A Multicentre Comparison of Trimoprostil and Cimetidine in the Treatment of Duodenal Ulcer	<i>U. K. Trimoprostil Study Collaborative Group</i>	134
Ulcerative Colitis. Cancer Surveillance in an Unselected Population	<i>J. Rutegård, L. Åhsgren, R. Stenling & K. G. Janunger</i>	139
Effect of Pirenzepine on Oesophageal, Gastric, and Enteric Motor Function in Man	<i>E. E. Soffer, D. Kumar, K. Mridha, A. Das-Gupta, J. Britto & D. L. Wingate</i>	146
Effect of Pentagastrin and Cimetidine on Gastric Blood Flow Measured by Laser Doppler Flowmetry	<i>O. C. Lunde, K. Kvernebo & S. Larsen</i>	151
Comparison of the Effect of Single and Repeated Administrations of a Protease Inhibitor (Camostate) on Pancreatic Secretion in Man	<i>G. Adler, A. Müllenhoff, T. Bozkurt, B. Göke, I. Koop & R. Arnold</i>	158
Alternating Proliferative Capacity in the Rat Gastrointestinal Mucosa. Effects of E ₂ Prostaglandins and Indomethacin	<i>A. Uribe, C. Rubio & C. Johansson</i>	163
⁵¹ Cr-EDTA/ ¹⁴ C-Mannitol Intestinal Permeability Test. Clinical Use in Screening for Coeliac Disease	<i>K. J. Fotherby, E. P. Wraight & G. Neale</i>	171
Degradation of Amino Acids to Short-Chain Fatty Acids in Humans. An in Vitro Study	<i>H. S. Rasmussen, K. Holtug & P. B. Mortensen</i>	178
Maintenance Ranitidine Treatment after Haemorrhage from a Duodenal Ulcer. A 3-Year Study	<i>W. R. Murray, G. Cooper, G. Laferla, P. Rogers & M. Archibald</i>	183
Raised Plasma Thromboxane B ₂ Levels in Experimental Acute Necrotizing Pancreatitis in Rats. The Effects of Flunarizine, Dazoxiben, and Indomethacin	<i>B. van Ooijen, R. J. T. Ouwendijk, W. J. Kort, F. J. Zijlstra, J. E. Vincent, J. H. P. Wilson & D. L. Westbroek</i>	188
Prostanoid Imbalance in Experimental Acute Necrotizing Pancreatitis in Rats	<i>B. van Ooijen, W. J. Kort, F. J. Zijlstra, J. E. Vincent, J. H. P. Wilson & D. L. Westbroek</i>	193
Are Endoscopic and/or Histologic Findings in Gastroduodenal Mucosa a Predictor of Clinical Outcome in Peptic Ulcer Disease? A 1-Year Follow-up Study after Initial Healing with Either Cimetidine or Medium-Dose Antacid	<i>K.-Å. Jönsson, G. Bodemar, K. Norrby, A. Walan, C. Tysk & Ten Other Investigators</i>	199
A Microscopic and Immunodiagnostic Search for Giardiasis in Patients with Gastrointestinal Disorders	<i>M. C. Allison, E. L. Green, D. N. Bhattacharya, A. Smith & R. E. Pounder</i>	209
Peptic Ulcer Bleeding in Patients with and without Dyspepsia	<i>R. Jorde, P. G. Burhol & J. A. Johnson</i>	213
Abnormalities of the Migrating Motor Complex in Diabetics with Autonomic Neuropathy and Diarrhea	<i>C. P. Dooley, H. M. El Newihi, A. Zeidler & J. E. Valenzuela</i>	217
The Pentagastrin-Induced Gastric Acid Response in Humans	<i>R. Leth, L. Olbe & U. Haglund</i>	224
Microbial Flora and Bile Acid Metabolism in Patients with an Ileal Reservoir	<i>P. M. N. Y. H. Go, M. P. Van Dieijen-Visser, B. I. Davies, J. Lens & P. J. Brombacher</i>	229
Low-Dose Antacids and Pirenzepine in the Treatment of Patients with Non-Ulcer Dyspepsia and Erosive Prepyloric Changes. A Randomized, Double-Blind, Placebo-Controlled Trial	<i>R. Weberg & A. Berstad</i>	237
The Effects of Famotidine, 40 mg at Night, on 24-Hour Intra-gastric Acidity and Plasma Gastrin Concentration in Healthy Subjects	<i>S. Lanzon-Miller, R. E. Pounder, S. G. Ball, D. J. Dalgleish, J. Coward & A. O. Jackson</i>	244
Intestinal Absorption of Phosphatidylcholine and Triglyceride after Ileal Resection	<i>B. Åkesson & Å. Nilsson</i>	251

Abstracted in *Excerpta Medica*

Indexed in *Current Contents* and *Index Medicus*

Spanish edition distributed by Sanidad Ediciones, S.A.

Chinese edition distributed by The Shanghai Institute of Digestive Diseases

ISSN 0036-5521

Annual subscription (ten issues per year) USD 292.00

Publisher: Norwegian University Press (Universitetsforlaget/AS), P.O. Box 2959 Tøyen, Oslo 6, Norway.
U.S. office: Publications Expediting Inc., 200 Meacham Ave., Elmont, NY 11003, USA



Think about it

You make a clinical diagnosis. Do you ever consider the thought processes by which you arrived at it? Medical students and practitioners are often concerned with examples of diagnostic logic, but seldom consider them in the context of a general philosophy. Is diagnostic logic out on a limb, or is it based on the same principles as logic in general?

In *Logic in Medicine* doctors and philosophers combine to provide a coherent system of diagnostic logic with a broader view of the science and art of reasoning.

The abstract theory of theories has highly practical applications, and the authors explore the uses of computer technology and artificial intelligence systems as well as "fuzzy logic," "relevant logic," and the logic of economics and ethics. A book for all who wish to clear their minds of cant.

Just published

Price: Inland £5.95; Abroad £7.50; USA \$11.50
BMA members: Inland £5.45; Abroad £7.00; USA \$10.50
(including postage, by air abroad)
Payment must be enclosed with order

ORDER YOUR COPY NOW FROM
British Medical Journal, PO Box 295
London WC1H 9TE
or any leading medical bookseller

